ManishKohliMDProfessor, Division of Oncology

PubMed

• 251 citations
  Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
  Joerg Herrmann, Amir Lerman, Nicole P. Sandhu, Hector R. Villarraga, Sharon L. Mulvagh
  Mayo Clinic Proceedings. 2014-09-01
• 28 citations
  Management of Advanced Penile Cancer
  Jad Chahoud, Manish Kohli, Philippe E. Spiess
  Mayo Clinic Proceedings. 2021-03-01
• 100 citations
  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
  Manish Kohli, Yeung Ho, David W. Hillman, Jamie L. Van Etten, Christine Henzler
  Clinical Cancer Research. 2017-08-15

Journal Articles

• Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Thr...  
  Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zh..., J Clin Oncol, 1/29/2016
• Copy Number Variations in urine cell free DNAs as biomarkers in advanced prostate cancer  
  Kohli M, Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, OncoTargets & Therapy Journal, 1/1/2016
• Mutational landscapes of sequential prostate metastases and matched patient derived xenografts during Enzalutamide therapy  
  Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieb..., PLOS ONE, 1/1/2015
• ERNA: A graphic user interface-based tool optimized for large data analysis from high-throughput RNA sequencing  
  Yuan T, Huang X, Dittmar RL, Du M, Kohli M, Boardman L, Thibodeau SN, Wang L, BMC Genomics, 1/1/2014
• Health characteristics and sedentary behavior impact on prostate-specific antigen levels in a national US sample  
  Loprinzi PD, Kohli M, Journal of Physical Activity and Health, 1/1/2014
• Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients  
  Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ, Oncotarget, 1/1/2014
• Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology  
  Qin R, Kohli M, Pers. Med., 1/1/2013
• Cabozantinib Promising in Castration-Resistant Prostate Cancer (Expert Commentary)  
  Kohli M, Clinical Oncology, 1/1/2013
• An oberservational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer  
  Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M, Journal of Men's Health, 1/1/2012
• Thrombin and thrombin receptor expression in prostate cancer  
  Kaushal V, Kohli M, Richard D, Chiles W, Mukunyadzi P, Prostate., 1/21/2005
• Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma  
  Alikhan MA, Spencer HJ, Kohli M, J Clin Oncol, 1/1/2005
• Stage specific expression of VEGF A and D in prostate cancer  
  Kaushal V, Dennis R, Mukunyadzi P, Siegel E, Johnson D, Kohli M, Clin Cancer Res, 1/1/2005
• Join now to see all

Books/Book Chapters

• Germ Cell Tumor 
  Chapter: Medical Management of germ cell tumors. 
  Kohli M, Zhang B, Costello BASpringer2015
• DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology 
  Chapter: Hormonal agents. 
  Page 278 - 289Goetz MP, Erlichman C, Loprinzi CL, Kohli MEditors: DeVita VT Jr; Lawrence TS; Rosenberg SA.Wolters Kluwer, PhiladelphiaEdition 10th,2015
• Oncology In Primary Care 
  Chapter: Principles of antieoplastic therapy. 
  Page 217 - 236Kohli M, Lawrence TS, Reddy NM, Chinratanalab W, Goodman SA, Savani BN, Abrams DI, Hochster HSEditors: Rose MG; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia2013
• Oncology in Primary Care 
  Chapter: Principles of Anti-Neoplastic Therapy. 
  M Kohli, T Lawrence, S Goodman, B Savani, W Chinratanalab, N Reddy, D Abrams, H HochsterEditors: MG Rose, VT Devita Jr, TS Lawrence SA Rosenberg.Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia2012
• DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology 
  Chapter: Endocrine manipulation. 
  Page 508 - 219Goetz MP, Erlichman C, Kohli M, Loprinzi CLEditors: DeVita VT Jr; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition 9th,2011
• CANCER: Principles and Practice of Oncology 
  Chapter: Endocrine Manipulations. 
  Goetz MP, Erlichman C, Loprinzi CL, Kohli M2010
• Encyclopedia of Cancer 
  Chapter: Hormonal Therapy in Prostate Cancer. 
  Kohli M, Tindall DEdition 3rd,2010
• Geriatric Nutrition The Health Professional's Handbook 
  Chapter: Impact of nutrition on the age related declines in heamatopoiesis. 
  Kohli M, Lipschitz DA, Chatta GSJones & Bartlett Publishers, AspenEdition 2nd,1999
• Join now to see all

Abstracts/Posters

• Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P)
  Manish Kohli, MD, ASCO GU Symposium, 1/1/2016
• Comparative analysis of neuroendocrine phenotype in metastases from advanced prostate cancer and their corresponding primary tumor.
  Jimenez RE, Abbas J, Cheville JC, Kohli M, Laboratory Investigation, 1/1/2016
• Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P)
  Manish Kohli, MD, ASCO Annual Meeting, 1/1/2016
• The association of JAK2 polymorphisms with prognosis in castration-resistant prostate cancer (CRPC)
  Manish Kohli, MD, ASCO GU Symposium, 1/1/2016
• Variation in trmt11 gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (crpc) patients.
  Zhang BYM, Mahoney DW, Riska SM, Cerhan JR, Teixeira Ribeiro RJ, Medeiros R, Monteiro C, Nogueira A, Mauricio J, Fraga AM, Calais-Da-Silva F, Costello BA, Dronca RS, P..., J Clin Oncol, 1/20/2015
• Feasibility Analysis of Pathology and Genetic Yield from a Prospective Trial of Tissue Biopsies in Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  Manish Kohli, MD, 22nd Annual Prostate Cancer Foundation Scientific Retreat, 1/1/2015
• Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
  Wang, L, Xia S, Du M, Ditmar R, Yuan T, Guo Y, Wang Y, Lee A, Tschannen M, Worthey E, Jacobs H, Huang CC, Kohli M, AACR Annual Meeting, 1/1/2015
• Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate-resistant prostate cancer (mcrpc).
  Jimenez RE, Sicotte H, Barman P, Sinnwell JP, Eiken PW, Atwell TD, McMenomy BP, Tan W, Wu K, Bryce AH, Ho TH, Pitot HC, Quevedo F, Costello BA, Dronca RS, Moynihan TJ,..., J Clin Oncol, 1/1/2015
• Association of germline variation with androgen ablation (aa) failure in advanced hormone-sensitive prostate cancer (hspc).
  Kochuparambil ST, Zhang BY, Riska SM, Mahoney DW, McDonnell S, Lee AM, Quevedo F, Costello BA, Pitot HC, Ribeiro R, Medeiros R, Monteiro C, Nogueira A, Mauricio J, Fra..., J Clin Oncol, 1/1/2015
• Effect of metastatic site biopsy on circulating tumor cell (ctc) count in castrate resistant prostate cancer (crpc) stage.
  Kohli M, Eiken PW, McMenomy BP, Atwell TD, Tan W, Qin R, Carlson R, Campion MB, Wang LW, Costello BA, Pitot HC, Quevedo F, Scheel EA, Ho TH, Bryce AH, Paz-Fumagalli R,..., J Clin Oncol, 1/1/2015
• Androgen receptor (ar) based biomarker association with response to abiraterone acetate/prednisone (aa/p) in metastatic castrate resistant prostate cancer (mcrpc).
  Kohli M, Wang LG, Sicotte H, Qin R, Carlson R, Eckel-Passow J, Tan W, Wu K, Dehm S, Eiken PW, Jimenez RE, Cernigliaro J, Quevedo F, Costello BA, Pitot HC, Moynihan TJ,..., J Clin Oncol, 1/1/2015
• Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.
  Petrylak DP, Tagawa ST, Kohli M, Tang SD, Zhang H, Hamid O, Kauh JS, Walgren RA, Chi KN, J Clin Oncol, 1/1/2015
• Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.
  Haas NB, Manola J, Flaherty K, Uzzo RG, Atkins MB, Dutcher JP, Wood CG, Kane CJ, Jewett MAS, Coomes B, Matin SF, Kuzel T, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puza..., J Clin Oncol, 1/1/2015
• A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
  Kohli M, Qin R, Wang L, Sicotte H, Carlson R, Tan W, Jimenez RE, Wang L, Eckel-Passow J, Costello BA, Pitot HC, Quevedo F, Dronca RS, Wu K, Moynihan TJ, Ho TH, Bryce A..., J Clin Oncol, 1/1/2015
• Effect of metastatic site biopsy on circulating tumor cell (CTC) count in castrate resistant prostate cancer (CRPC) stage.
  Manish Kohli, MD, ASCO GU Symposium, 1/1/2015
• Feasibility Analysis of Pathology and Genetic Yield from a Prospective Trial of Tissue Biopsies in Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  Manish Kohli, MD, ASCO GU Symposium, 1/1/2015
• Change in Circulating Tumor cell (CTC) counts as predictive marker of response in chemotherapy naïve castrate resistant metastatic prostate cancer (CRPC) treated with ...
  Manish Kohli, MD, ASCO GU Symposium, 1/1/2015
• Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC)
  Manish Kohli, MD, ASCO GU Symposium, 1/1/2015
• A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC)
  Manish Kohli, MD, ASCO Annual Meeting, 1/1/2015
• Impact of biopsy of metastases on circulating tumor cell (CTC) counts in castrate resistant prostate cancer (CRPC)
  Manish Kohli, MD, 18th ECCO - 40th ESMO European Cancer Congress, 1/1/2015
• Androgen Receptor V9 (ARV9) mRNA expression in metastatic tissue is associated with early resistance to Pre-Chemotherapy Abiraterone Acetate/Prednisone (AA/P)
  Manish Kohli, MD, 22nd Annual Prostate Cancer Foundation Scientific Retreat, 1/1/2015
• Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase II...
  Sweeney C, Chen YH, Carducci MA, Liu G, Jarrard DF, Eisenberger MA, Wong YN, Hahn NM, Kohli M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shevrin DH, Hussain M, Garc..., J Clin Oncol, 1/1/2014
• Exosomal microrna as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mcrpc).
  Kohli M, Huang XY, Yuan TZ, Sun ZF, Costello BA, Quevedo F, Tan W, Nandy D, Longenbach S, Wang L, J Clin Oncol, 1/1/2014
• Chemohormonal therapy versus hormonal therapy for hormone naive high volume newly metastatic prostate cancer (prca): ecog led phase iii randomized trial.
  Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M, Wong Y, Hahn NM, Kohli M, Vogelzang N, Cooney M, Dreicer R, Picus J, Shevrin D, Hussain M, Garcia J, Di..., Ann Oncol, 1/1/2014
• Exosomal mir-1290 and mir-375 as prognostic markers in metastatic castrate resistant prostate cancer.
  Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar RL, Sun Z, Lu Y, Thibodeau SN, Boardman L, Kohli M, Wang L, Cancer Res, 1/1/2014
• Join now to see all

Lectures

• Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and ... 
  2019 ASCO Annual Meeting - 6/1/2019
• A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of lo... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Research Program in Advanced GU Malignancies 
  Mayo Clinic, Rochester, MN - 1/1/2016
• In search of a Response Biomarker in Advanced Prostate Cancer Therapeutics 
  University of California Davis, Davis, CA - 1/1/2016
• Liquid Biopsy Program in Advanced GU Cancers 
  Mayo Clinic, Rochester, MN - 1/1/2016
• In Search of Response Biomarkers in Advanced Prostate Cancer Therapeutics 
  Mayo Clinic, Rochester, MN - 1/1/2016
• Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) 
  Park Nicolett Health System, Minneapolis, MN - 1/1/2015
• Value of Blood Banking in India 
  Chicago, IL - 1/1/2015
• Biomarker development in advanced prostate cancer and clinical applications. 
  University of Illinois at Urbana-Champaign, Urbana, IL - 1/1/2015
• ACCP Prostate Cancer Course 
  Mayo Clinic, Rochester, MN - 1/1/2015
• Ethical Considerations in Pregnancy Related Research 
  Kawagoe, Japan - 1/1/2015
• How to Use National Datasets 
  1/1/2014
• Initiated Hospital to Hospital Collaboration between Mayo Clinic Cancer Center and Seoul National Hospital 
  Bundang Hospital, South Korea - 1/1/2014
• Genomic Application in Prostate Cancer 
  Seoul, South Korea - 1/1/2014
• Updates in the treatment of Metastatic prostate cancer and metastatic kidney cancer. 
  Geneva, Switzerland - 1/1/2014
• Molecular Genetics in Prostate Cancer 
  Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India - 1/1/2014
• Management of Hepatocellular Cancer and Liver Metastasis 
  Ludhiana, India - 1/1/2014
• Renal Cell and Bladder Cancer Management in 2014 
  1/1/2014
• ASCO 2013: Updates in GU Oncology 
  Mayo Medical School, Rochester, MN - 1/1/2013
• Coagulation and Pregnancy and Regional Anesthesia/Analgesia 
  Bangkok, Thailand - 1/1/2013
• Prostate Cancer Medically Optimized Genome Enhanced Therapy in Castrate-Resistant Stage (PROMOTE) 
  1/1/2013
• Advances in Cancer Genetics Applied to Genito-Urinary Oncology 
  1/1/2013
• ASCO 2012: Updates in GU Oncology 
  Mayo Medical School, Rochester, MN - 1/1/2012
• Evaluation of ERG Expression in Metastatic Carcinoma of the Prostate 
  Vancouver, British Columbia, Canada - 1/1/2012
• ASCO 2012: Updates in Genitourinary Oncology 
  Minneapolis, MN - 1/1/2012
• Join now to see all